The Impact of Stress on Inflammatory Dermatologic Diseases: A Narrative Review

Öz

In this review, the effects of stress on inflammatory dermatologic diseases were examined from a psychoneuroim-imunological perspective. The mechanisms by which psychological stress influences the relationships between the immune system and the skin have been evaluated in the context of major inflammatory skin diseases supported by current literature. The role of stress in the pathogenesis of these disorders, its effect on disease exacerbations, and its importance in treatment response were presented based on current literature findings. In addition, the effects of stress management approaches on the prognosis of inflammatory dermatological diseases were discussed. Our review particularly focused on the role of psychological stress in the exacerbation and course of psoriasis, atopic dermatitis, acne vulgaris, rosacea, urticaria, seborrheic dermatitis, and lichen planus, which constitute a substantial proportion of patients attending dermatology clinics. Findings from our study and the existing literature demonstrate that dermatologic lesions, which are readily visible on the skin, may elicit feelings of shame and guilt and consequently increase psychological stress. This heightened stress level appears to play a significant role in disease flares. Therefore, clinicians should not overlook the psychological burden associated with dermatologic diseases, as addressing this bidirectional interaction is essential for breaking the vicious cycle that perpetuates disease activity. Accordingly, dermatologic and psychological treatment approaches should be integrated. In particular, performing disease-specific severity assessments, systematically screening psychological symptoms using validated instruments, and providing individualized psychiatric support interventions especially when implemented early, may contribute to improvements in patients’ quality of life and may positively influence disease progression.

Anahtar Kelimeler

• inflammation
• stress, psychological
• immunology
• skin diseases
• disease progression

Destekleyen Kurum

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Proje Numarası

Bu çalışma için bir proje numarası bulunmamaktadır.

Etik Beyan

Ethical approval was not required for this review article, as it is based on previously published studies and does not involve human participants or animals.

Teşekkür

I would like to thank Professor Çiçek Hocaoğlu for her kind support throughout the writing process of this article.

Stresin inflamatuar dermatolojik hastalıklar üzerine etkisi: Geleneksel bir derleme

Öz

Bu derlemede, stresin inflamatuar dermatolojik hastalıklar üzerindeki etkisi psikonöroimmünolojik açıdan incelenmiştir. Psikolojik stresin bağışıklık sistemi ile deri arasındaki ilişkileri hangi mekanizmalarla etkilediği, başlıca inflamatuar deri hastalıkları özelinde literatür bilgileri eşliğinde değerlendirilmiştir. Bu hastalıkların patogenezinde stresin rolü, alevlenmeler üzerindeki etkisi ve tedaviye yanıt açısından önemi literatür bulguları eşliğinde sunulmuştur. Ayrıca stres yönetimi yaklaşımlarının inflamatuar deri hastalıklarının prognozuna etkileri değerlendirilmiştir. Çalışmamızda dermatoloji polikliniklerinde ciddi bir hasta popülasyonu oluşturan psöriazis, atopik dermatit, akne vulgaris, rozasea, ürtiker, seboreik dermatit ve liken planus hastalıklarında psikolojik stresin bu hastalık-ların alevlenmelerindeki ve seyrindeki rolleri üzerinde durulmuştur. Çalışmamızın sonuçları ve literatürdeki bulgular, ciltte kolaylıkla fark edilebilen dermatolojik lezyonların kişilerde utanç ve suçluluk duygularını tetikleyebildiğini ve psikolojik stresi artırdığını; bu artan stres düzeyinin ise hastalığın alevlenmesinde önemli bir rol oynadığını ortaya koymaktadır. Bu karşılıklı etkileşimle oluşan kısır döngünün kırılabilmesi için dermatolojik hastalıkların taşıdığı psikolojik yükün klinisyenler tarafından göz ardı edilmemesi gerektiği belirtilmiştir. Bu nedenle hem dermatolojik hem de psikolojik tedavi yaklaşımları birlikte ele alınmalıdır. Özellikle doğru hasta gruplarında, hastalığa özgü şiddet skorlamalarının yapılması ve psikolojik belirtilerin geçerli ölçeklerle taranması, ardından bireyselleştirilmiş psikiyatrik müdahalelerin uygulanması, erken dönemde gerçekleştirildiğinde hem yaşam kalitesinin iyileştirilmesine hem de hastalığın seyrinin olumlu yönde etkilenmesine katkı sağlayabilir.

Anahtar Kelimeler

• inflamasyon
• deri hastalıkları
• psikolojik stress
• immünoloji
• hastalık alevlenmesi

Destekleyen Kurum

Bu araştırma, kamu, ticari veya kâr amacı gütmeyen sektörlerdeki fon sağlayıcı kurumlardan herhangi bir özel destek (hibe) almamıştır.

Proje Numarası

Bu çalışma için bir proje numarası bulunmamaktadır.

Etik Beyan

Bu derleme makalesi için etik kurul onayı gerekmemiştir; çünkü çalışma daha önce yayımlanmış araştırmalara dayanmaktadır ve insan katılımcılar veya hayvanlar üzerinde herhangi bir araştırma içermemektedir.

Teşekkür

Bu makaleyi yazma sürecimde desteklerini esirgemeyen saygıdeğer Çiçek Hocaoğlu’na teşekkürlerimi sunarım.

Kaynakça

1. 1. Chu B, Marwaha K, Sanvictores T, Awosika AO, Ayers D. Physiology, stress reaction. In: StatPearls. Trea-sure Island (FL): StatPearls Publishing; 2024.
2. 2. Mifsud KR, Reul JMHM. Mineralocorticoid and glucocorticoid receptor-mediated control of genomic responses to stress in the brain. Stress. 2018;21(5):389–402.
3. 3. Ketchesin KD, Stinnett GS, Seasholtz AF. Cor-ticotropin-releasing hormone-binding protein and stress: from invertebrates to humans. Stress. 2017;20(5):449–64.
4. 4. Godoy LD, Rossignoli MT, Delfino-Pereira P, Garcia-Cairasco N, Umeoka EH de L. A comprehensive overview on stress neurobiology: basic concepts and clinical implications. Front Behav Neurosci. 2018;12:127.
5. 5. Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodege-neration. Ageing Res Rev. 2005;4(2):141–94.
6. 6. Eisen AM, Bratman GN, Olvera-Alvarez HA. Susceptibility to stress and nature exposure: unveiling differential susceptibility to physical environments; a randomized controlled trial. PLoS One. 2024;19(4):e0299965.
7. 7. Gu HF, Tang CK, Yang YZ. Psychological stress, immune response, and atherosclerosis. Atherosclerosis. 2012;223(1):69–77.
8. 8. Tottoli EM, Dorati R, Genta I, Chiesa E, Pisani S, Conti B. Skin wound healing process and new emer-ging technologies for skin wound care and regeneration. Pharmaceutics. 2020;12(8):735.

9. 9. Lumen Learning. Layers of the skin. 2025.
10. 10. Tausk F, Elenkov I, Moynihan J. Psychoneuro-immunology. Dermatol Ther 2008;21(1):22–31.
11. 11. Joëls M, Baram TZ. The neuro-symphony of stress. Nat Rev Neurosci 2009;10(6):459–66.
12. 12. Bao AM, Meynen G, Swaab DF. The stress sys-tem in depression and neurodegeneration: focus on the human hypothalamus. Brain Res Rev 2008;57(2):531–53.
13. 13. King SB, Toufexis DJ, Hammack SE. Pituitary adenylate cyclase activating polypeptide (PACAP), stress, and sex hormones. Stress 2017;20(5):465–75.
14. 14. Zhang JM, An J. Cytokines, inflammation and pain. Int Anesthesiol Clin 2007;45(2):27–37.
15. 15. Han QQ, Yu J. Inflammation: a mechanism of depression? Neurosci Bull 2014;30(3):515–23.
16. 16. Dinarello CA. Proinflammatory cytokines. Chest 2000;118(2):503–8.
17. 17. Köhler CA, Freitas TH, Stubbs B, et al. Periphe-ral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disor-der: systematic review and meta-analysis. Mol Neurobiol 2018;55(5):4195–206.
18. 18. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neu-ropsychopharmacol Biol Psychiatry 1995;19(1):11–38.
19. 19. Levine J, Barak Y, Chengappa KNR, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999;40(4):171–6.
20. 20. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002;26(5):643–52.
21. 21. Capuron L, Ravaud A, Miller AH, Dantzer R. Baseline mood and psychosocial characteristics of pati-ents developing depressive symptoms during interleu-kin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun. 2004;18(3):205–13.
22. 22. Chu B, Marwaha K, Sanvictores T, Awosika AO, Ayers D. Physiology, stress reaction. In: StatPearls. Trea-sure Island (FL): StatPearls Publishing; 2024.
23. 23. Reiche EMV, Nunes SOV, Morimoto HK. Stress, depression, the immune system, and cancer. Lan-cet Oncol 2004;5(10):617–25.
24. 24. Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol 2014;10(4):217–24.
25. 25. Johnson JD, Barnard DF, Kulp AC, Mehta DM. Neuroendocrine regulation of brain cytokines after psyc-hological stress. J Endocr Soc 2019;3(7):1302.
26. 26. Frank MG, Fonken LK, Annis JL, Watkins LR, Maier SF. Stress disinhibits microglia via down-regulation of CD200R: a mechanism of neuroinflamma-tory priming. Brain Behav Immun 2018;69:62–73.
27. 27. Fonken LK, Frank MG, Gaudet AD, et al. Neu-roinflammatory priming to stress is differentially regula-ted in male and female rats. Brain Behav Immun 2018;70:257–67.
28. 28. Biazus Soares G, Mahmoud O, Yosipovitch G, Mochizuki H. The mind–skin connection: a narrative review exploring the link between inflammatory skin diseases and psychological stress. J Eur Acad Dermatol Venereol 2024;38(5):821–34.
29. 29. Cortés H, Rojas-Márquez M, Del Prado-Audelo ML, Reyes-Hernández OD, González-Del Carmen M, Leyva-Gómez G. Alterations in mental health and qua-lity of life in patients with skin disorders: a narrative review. Int J Dermatol 2022;61(7):783–91.
30. 30. Vidal Yucha SE, Tamamoto KA, Kaplan DL. The importance of the neuro-immuno-cutaneous system on human skin equivalent design. Cell Prolif 2019;52(6):e12677.
31. 31. Bylund S, Von Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermati-tis: a systematic review. Acta Derm Venereol 2020;100(12):5765.
32. 32. Pavlis J, Yosipovitch G. Management of itch in atopic dermatitis. Am J Clin Dermatol 2018;19(3):319–32.
33. 33. Yosipovitch G, Fleischer AB. Itch associated with skin disease: advances in pathophysiology and emerging therapies. Am J Clin Dermatol 2003;4(9):617–22.
34. 34. Park H, Kim K. Association of perceived stress with atopic dermatitis in adults: a population-based study in Korea. Int J Environ Res Public Health 2016;13(8):760.
35. 35. Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M. Nerve growth factor and subs-tance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 2002;147(1):71–9.
36. 36. Oh SH, Bae BG, Park CO, et al. Association of stress with symptoms of atopic dermatitis. Acta Derm Venereol 2010;90(6):582–8.
37. 37. Cai X, Wang S, Wang C, Liu L, Wang J, Shen Y, et al. Epidemiology of mental health comorbidity in patients with atopic dermatitis: an analysis of global trends from 1998 to 2022. J Eur Acad Dermatol Vene-reol. 2024;38(3):496–512.
38. 38. Xie QW, Dai X, Tang X, Chan CHY, Chan CLW. Risk of mental disorders in children and adolescents with atopic dermatitis: a systematic review and meta-analysis. Front Psychol. 2019;10:1773.
39. 39. Michalek IM, Loring B, John SM. Global report on psoriasis. Geneva: World Health Organization; 2016.
40. 40. Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoria-tic arthritis: a focus on apremilast. Drug Des Devel Ther 2013;7:201–10.
41. 41. Kannan S, Heller MM, Lee ES, Koo JY. The role of tumor necrosis factor-alpha and other cytokines in depression: what dermatologists should know. J Derma-tolog Treat 2013;24(2):148–52.
42. 42. Rosenblat JD, Cha DS, Mansur RB, McIntyre RS. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychop-harmacol Biol Psychiatry 2014;53:23–34.
43. 43. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psyc-hopharmacology (Berl) 2003;170(4):429–33.
44. 44. Xiao Y, Zhang X, Luo D, et al. The efficacy of psychological interventions on psoriasis treatment: a systematic review and meta-analysis of randomized cont-rolled trials. Psychol Res Behav Manag 2019;12:97.
45. 45. Henry AL, Kyle SD, Bhandari S, Chisholm A, Griffiths CEM, Bundy C. Measurement, classification and evaluation of sleep disturbance in psoriasis: a sys-tematic review. PLoS One. 2016;11(6):e0157845.
46. 46. Devrimci-Ozguven H, Kundakci N, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 2000;14(4):267–71.
47. 47. Böhm D, Stock Gissendanner S, Bangemann K, et al. Perceived relationships between severity of psoria-sis symptoms, gender, stigmatization and quality of life. J Eur Acad Dermatol Venereol 2013;27(2):220–6.
48. 48. Abbott R, Whear R, Nikolaou V, et al. Tumour necrosis factor-α inhibitor therapy in chronic physical illness: a systematic review and meta-analysis of the effect on depression and anxiety. J Psychosom Res 2015;79(3):175–84.
49. 49. Krishnadas R, Nicol A, Sassarini J, et al. Circu-lating tumour necrosis factor is highly correlated with brainstem serotonin transporter availability in humans. Brain Behav Immun 2016;51:29–38.
50. 50. Tohid H, Aleem D, Jackson C. Major depression and psoriasis: a psychodermatological phenomenon. Skin Pharmacol Physiol 2016;29(4):220–30.
51. 51. Beretta L, Cossu M, Marchini M, et al. A poly-morphism in the human serotonin 5-HT2A receptor gene may protect against systemic sclerosis by reducing plate-let aggregation. Arthritis Res Ther 2008;10(5):R102.
52. 52. Tong N, Zhang Y, Yang A, Dai X, Hao S. The potency of common proinflammatory cytokines measu-rement for revealing the risk and severity of anxiety and depression in psoriasis patients. J Clin Lab Anal 2022;36(9):e24643.
53. 53. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Der-matol 2014;134(6):1527–34.
54. 54. Zouboulis CC, Böhm M. Neuroendocrine regula-tion of sebocytes: a pathogenetic link between stress and acne. Exp Dermatol 2004;13(4):31–5.
55. 55. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016;74(5):945–73.e33.
56. 56. Tan JKL, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol 2015;172(S1):3–12
57. 57. Mattii M, Lovászi M, Garzorz N, et al. Sebocytes contribute to skin inflammation by promoting the diffe-rentiation of T helper 17 cells. Br J Dermatol 2018;178(3):722–30.
58. 58. Lynn DD, Umari T, Dunnick CA, Dellavalle RP. The epidemiology of acne vulgaris in late adolescence. Adolesc Health Med Ther 2016;7:13–17.
59. 59. Lee WJ, Jung HD, Chi SG, et al. Effect of dihyd-rotestosterone on the upregulation of inflammatory cyto-kines in cultured sebocytes. Arch Dermatol Res 2010;302(6):429–33.
60. 60. Arlt W, Stewart PM. Adrenal corticosteroid biosynthesis, metabolism, and action. Endocrinol Metab Clin North Am 2005;34(2):293–313.
61. 61. Lee WJ, Jung HD, Lee HJ, Kim BS, Lee SJ, Kim DW. Influence of substance-P on cultured sebocytes. Arch Dermatol Res 2008;300(6):311–6.
62. 62. Chen Y, Sun S, Yang H, Fei X, Zhang Y, Song J, et al. Global prevalence of mental health comorbidity in patients with acne: an analysis of trends from 1961 to 2023. Clin Exp Dermatol. 2025;50(6):1083–93.
63. 63. Samuels DV, Rosenthal R, Lin R, Chaudhari S, Natsuaki MN. Acne vulgaris and risk of depression and anxiety: a meta-analytic review. J Am Acad Dermatol. 2020;83(2):532–41.
64. 64. Huang YC, Cheng YC. Isotretinoin treatment for acne and risk of depression: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;76(6):1068–76.e9.
65. 65. Vallerand IA, Lewinson RT, Parsons LM, Lowerison MW, Frolkis AD, Kaplan GG, et al. Risk of depression among patients with acne in the U.K.: a popu-lation-based cohort study. Br J Dermatol. 2018;178(3):e194–5.
66. 66. Dumont S, Lorthe E, Loizeau A, et al. Acne-related quality of life and mental health among adoles-cents: a cross-sectional analysis. Clin Exp Dermatol 2025;50(4):795–803.
67. 67. Kansal NK, Bhatia R, Rawat VS, Sushantika, Vasisht S, Kumar A. Psychological aspects of acne vulga-ris: a narrative review. Clinical Dermatology Review 2025;9(2):109–12.
68. 68. Liu X, Cao Y, Wang W. Burden of and trends in urticaria globally, regionally, and nationally from 1990 to 2019: systematic analysis. JMIR Public Health Sur-veill 2023;9(1):e50114.
69. 69. Lee SJ, Ha EK, Jee HM, et al. Prevalence and risk factors of urticaria with a focus on chronic urticaria in children. Allergy Asthma Immunol Res 2017;9(3):212–9.
70. 70. Ensina LF, Min TK, Félix MMR, de Alcântara CT, Costa C. Acute urticaria and anaphylaxis: differences and similarities in clinical management. Front Allergy 2022;3:840999.
71. 71. Kolkhir P, Muñoz M, Asero R, et al. Autoimmu-ne chronic spontaneous urticaria. J Allergy Clin Immunol 2022;149(6):1819–31.
72. 72. Magen E, Merzon E, Ashkenazi S, et al. Anxiety and nonpsychotic mental disorders in acute urticaria. Brain Behav Immun Health 2025;48:101088.
73. 73. Choi GS, Nam YH, Park CS, et al. Anxiety, depression, and stress in Korean patients with chronic urticaria. Korean J Intern Med 2020;35(6):1507–15.
74. 74. Tole JW, Gratz KL, Dave ND, et al. Effect of psychological stress intervention for patients with chro-nic urticaria (CU). J Allergy Clin Immunol 2011;127(2):AB104.
75. 75. Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol 2018;179(2):282–9.
76. 76. Woo YR, Lim JH, Cho DH, Park HJ. Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int J Mol Sci 2016;17(9):1562.
77. 77. Chang HC, Huang YC, Lien YJ, Chang YS. As-sociation of rosacea with depression and anxiety: a sys-tematic review and meta-analysis. J Affect Disord 2022;299:239–45.
78. 78. Stearns V, Beebe KL, Iyengar M, Dube E. Pa-roxetine controlled release in the treatment of menopau-sal hot flashes: a randomized controlled trial. JAMA 2003;289(21):2827–34.
79. 79. Heisig M, Reich A. Psychosocial aspects of rosacea with a focus on anxiety and depression. Clin Cosmet Investig Dermatol 2018;11:103–7.
80. 80. Wang B, Huang Y, Tang Y, et al. Paroxetine is an effective treatment for refractory erythema of rosacea: primary results from the Prospective Rosacea Refractory Erythema Randomized Clinical Trial. J Am Acad Derma-tol 2023;88(6):1300–7.
81. 81. Jin R, Luo L, Zheng J. The trinity of skin: skin homeostasis as a neuro–endocrine–immune organ. Life (Basel) 2022;12(5):725.
82. 82. Choi JE, Di Nardo A. Skin neurogenic inflam-mation. Semin Immunopathol 2018;40(3):249–59.
83. 83. Vidal Yucha SE, Tamamoto KA, Kaplan DL. The importance of the neuro-immuno-cutaneous system on human skin equivalent design. Cell Prolif 2019;52(6):e12677.
84. 84. Dantzer R. Neuroimmune interactions: from the brain to the immune system and vice versa. Physiol Rev 2018;98(1):477–527.
85. 85. Pyo HJ, An X, Cho H. The role of free fatty acid receptor pathways in a selective regulation of TRPA1 and TRPV1 by resolvins in primary sensory neurons. J Cell Physiol 2022;237(9):3651–60.
86. 86. De Moura JC, Noroes MME, Rachetti VDPS, et al. The blockade of transient receptor potential ankirin 1 (TRPA1) signalling mediates antidepressant- and anxiolytic-like actions in mice. Br J Pharmacol 2014;171(18):4289–99.
87. 87. Yang X, Cai M. New insights into the mutual promotion of rosacea, anxiety, and depression from neu-roendocrine immune aspects. Clin Cosmet Investig Der-matol 2023;16:1363.
88. 88. Orleans RJ, Li L, Kim MJ, et al. FDA approval of paroxetine for menopausal hot flushes. N Engl J Med 2014;370(19):1777–9.
89. 89. Goldust M, Ranjkesh MR, Amirinia M, Golfo-roushan F, Rezaee E, Rezazadeh Saatlou MA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physi-cian 2015;91(3):185–90.
90. 90. Schwartz JR, Mesenger AG, Tosti A, et al. A comprehensive pathophysiology of dandruff and seborr-heic dermatitis–towards a more precise definition of scalp health. Acta Derm Venereol 2013;93(2):131–7.
91. 91. Polaskey MT, Chang CH, Daftary K, Fakhraie S, Miller CH, Chovatiya R. The global prevalence of seborr-heic dermatitis: a systematic review and meta-analysis. JAMA Dermatol 2024;160(8):846–55.
92. 92. Misery L, Touboul S, Vinçot C, et al. Stress and seborrheic dermatitis. Ann Dermatol Venereol 2007;134(11):833–7.
93. 93. Chen J, Li C, Chang CH, Polaskey MT, Chovati-ya R. Prevalence and severity of mental health symptoms with seborrheic dermatitis: a systematic review and meta-analysis. Int J Dermatol. 2025;1–3.
94. 94. Tekin B, Xie F, Lehman JS. Lichen planus: what is new in diagnosis and treatment? Am J Clin Dermatol 2024;25(5):735–64.
95. 95. National Organization for Rare Disorders. Lic-hen planus: symptoms, causes, treatment. National Orga-nization for Rare Disorders; 2025.
96. 96. De Porras-Carrique T, González-Moles MÁ, Warnakulasuriya S, et al. Depression, anxiety, and stress in oral lichen planus: a systematic review and meta-analysis. Clin Oral Investig 2022;26(2):1391–1403.
97. 97. Alnazly E, Absy N, Sweileh I. Depression, anxiety, stress associated with lichen planus in Jorda-nian women and the impact on their quality of life. Int J Womens Health 2023;15:1883.